First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination with Other Antineoplastic Agents in Participants with Advanced Solid Tumor

MC #23-06

NCT #
NCT05768139
Condition(s)
Breast Cancer, Solid Tumor
Molecular Target(s)
PI3Kα
Drug Classification(s)
Small Molecule
Agents(s)
STX-478
Phase(s)
I/II

Mechanism of Action

STX-478 is a PI3Kα small molecule inhibitor.

Purpose

  • How much of the study drug can be given with an acceptable level of side effects
  • The effects of the study drug (good and bad)
  • How much of the study drug is absorbed into the blood and how fast it is removed

Location

MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.